2T Quadruple Screening (Delfia)

2T Quadruple Screening (DELFIA)

2T Quadruple Screening (DELFIA) is a second-trimester prenatal screening test that assesses the risk of certain chromosomal abnormalities and neural tube defects in the developing fetus. The test uses DELFIA® (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) technology for accurate measurement of maternal serum markers.

Test Includes

The screening measures four biochemical markers in maternal blood:

• Alpha-Fetoprotein (AFP)
• Human Chorionic Gonadotropin (hCG) / Free β-hCG
• Unconjugated Estriol (uE3)
• Inhibin A

Recommended During

• 15 to 20 weeks of pregnancy (Second Trimester)
• Most effective when performed within the recommended gestational age window.

Clinical Significance

The test helps estimate the risk of:

• Down Syndrome (Trisomy 21)
• Edwards Syndrome (Trisomy 18)
• Neural Tube Defects (e.g., Spina Bifida)
• Certain abdominal wall defects and other fetal developmental abnormalities.

Sample Required

• Maternal blood (Serum)

Preparation

• No fasting required.
• Accurate gestational age and maternal details are essential for proper risk calculation.

Benefits

• Non-invasive and safe for both mother and baby.
• Provides enhanced screening performance compared to double and triple marker tests through the inclusion of Inhibin A.

Interpretation

• Results are reported as risk estimates, not a definitive diagnosis.
• High-risk results may require follow-up investigations such as detailed ultrasound, genetic counseling, NIPT, or diagnostic procedures like amniocentesis.